Jaguar Land Rover to invest £15 billion to accelerate its ‘electrification path’
The Tata Motors-owned company said the investment would cover “industrial footprint, vehicle programmes, autonomous, AI and digital technologies and people skills�
Jaguar Land Rover has announced a plan to invest £15 billion over the next five years to reposition itself as an electric-first, modern luxury carmaker by 2030.
The Tata Motors-owned company on Wednesday (19) said the investment would cover “industrial footprint, vehicle programmes, autonomous, AI and digital technologies and people skills”.
It also said its Halewood plant in Merseyside would become an all-electric production facility and its next-generation medium-size SUV architecture would now be pure-electric.
JLR said the first of its next-generation medium-size luxury SUVs would be an all-electric model from the Range Rover family.
To be built at Halewood, they will be launched in 2025.
The plans are seen as the British automaker’s efforts to catch up with its German rivals Mercedes and BMW which have already made strides in the electric vehicle space.
JLR’s engine manufacturing centre in Wolverhampton which currently makes Ingenium internal combustion engines for its vehicles will produce electric drive units and battery packs for next-generation vehicles. The facility will be renamed the Electric Propulsion Manufacturing Centre to reflect the change.
The British carmaker, bought by Tata Motors from Ford in 2008, has also set a target to achieve a net cash-positive position by 2025.
JLR chief executive officer Adrian Mardell said the company was “accelerating” its “electrification path.
“This investment enables us to deliver to our modern luxury electric future, developing new skills, and reaffirming our commitment to be carbon net zero by 2039," Mardell said in a statement.
The company, however, said it will retain its modular longitudinal architecture (MLA) on which Range Rover and Range Rover Sport are built, offering internal combustion engine, hybrid and battery electric vehicle (BEV) options.
It said the strategy would give its flexibility to meet the needs of different markets which “are moving at different speeds towards carbon net zero targets,” although electrification in certain markets increases”.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.